drug · protein
afamelanotide acetate
Marketedupdated 5mo agoby Clinuvel Pharmaceuticals Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval, with an approval for erythropoietic protoporphyria.
targets
Melanocyte-stimulating hormone receptor
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 8, 2026
8 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Jan 20, 2033method-of-use (U-2638)US 8334265
FDA exclusivities (1)
- Oct 8, 2026ODE-270Orphan Drug (7y)8d
News(2)
- Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodLeo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…fiercebiotech · 1mo ago
- Australian biopharma Clinuvel to shed up to 20% of workforce in move to USAustralian biopharma Clinuvel Pharmaceuticals is moving its headquarters to the U.S.— but up to a fifth of the company’s workforce won’t be staying for the trans-Pacific pivot.fiercebiotech · 2mo ago
Data sources
last refreshed 49m ago
Found something off?
comments(0)
5-min edit window · permanent after that